In contrast to these local treatments, the systemic administration of recombinant human IFN-γ in patients with acute myeloblastic leukemia and myelodysplastic syndromes did not lead to hematological responses and was only poorly tolerated [38]. The gene discussed is IFNG; the disease is acute myeloid leukemia.